Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anact C is a plasma-derived human activated protein C (APC) concentrate developed by KM Biologics. It is primarily indicated for the treatment of patients with congenital protein C deficiency, a rare condition that predisposes individuals to severe thrombotic events such as purpura fulminans, deep vein thrombosis, and acute pulmonary thromboembolism. As a protein replacement therapy, Anact C provides the active form of protein C, a natural anticoagulant that regulates the coagulation cascade by inactivating factors Va and VIIIa. This inactivation limits the production of thrombin and prevents pathological clot formation. The drug is approved in Japan and is administered intravenously.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on activated protein C (KM Biologics).